Sorrento Therapeutics, Inc.

382 articles about Sorrento Therapeutics, Inc.

• Sorrento Therapeutics, Inc. The Unexpected Death Of Its Chief Business Officer

  8/1/2014

• Sorrento Therapeutics, Inc. Awarded Grant From The National Institutes Of Health For The Development Of A Small Molecule Myc Inhibitor

  7/21/2014

• Sorrento Therapeutics, Inc. Awarded Grant From The National Institutes of Health (NIH) For The Development Of A Small Molecule Myc Inhibitor

  7/21/2014

• Sorrento Therapeutics, Inc. Awarded Up To $2.6 Million From The National Institutes of Health (NIH) For The Development Of New Anti-Bacterial Bispecific Antibodies And Antibody Formulated Drug Conjugates

  7/1/2014

• Morphotek Inc. And Sorrento Therapeutics, Inc. Sign An Exclusive Research And Option Agreement To Generate And Develop Morphotek Antibody Drug Conjugates

  6/25/2014

• Sorrento Therapeutics, Inc. To Present At Biotechnology Industry Organization (BIO) Business Forum

  6/23/2014

• Sorrento Therapeutics, Inc. Announces Confidential Submission Of Draft Registration Statement For Initial Public Offering (IPO) Of Its Wholly-Owned Subsidiary Ark Animal Health With The SEC

  6/23/2014

• Sorrento Therapeutics, Inc. Announces Underwriters' Exercise Of Over-Allotment Option

  6/13/2014

• Sorrento Therapeutics, Inc. To Present At Jefferies and Co. 2014 Global Healthcare Conference

  6/2/2014

• Sorrento Therapeutics, Inc. Announces Proposed Public Offering Of Common Stock

  5/15/2014

• Sorrento Therapeutics, Inc. Announces Transfer Of Orphan Drug Designation Sponsorship for Intrathecal Resiniferatoxin From National Institutes of Health (NIH)

  5/13/2014

• Oxford Finance And Silicon Valley Bank Expand Existing Senior Credit Facility With Sorrento Therapeutics, Inc. To $12.5 Million

  4/17/2014

• Sorrento Therapeutics, Inc. Appoints Ian Walters As Senior Vice President Of Translational Medicine And Corporate Development

  4/8/2014

• Sorrento Therapeutics, Inc. Announces Presentation Of Data From Clinical Study Of Resiniferatoxin For Intractable Cancer Pain At ASRA Meeting

  4/4/2014

• Sorrento Therapeutics, Inc. Announces Key Presentation On Cynviloq At The American Association for Cancer Research Annual Meeting

  4/4/2014

• Sorrento Therapeutics, Inc. Appoints Mark Durand To Its Board Of Directors

  3/11/2014

• Sorrento Therapeutics, Inc. To Present At ROTH Capital Partners 26th Annual Growth Stock Conference

  3/6/2014

• Sorrento Therapeutics, Inc. Announces Three Presentations And A Satellite Symposium On Cynviloq™ At The 31st Annual Miami Breast Cancer Conference

  3/6/2014

• Sorrento Therapeutics, Inc. Hires Mike Royal As Senior Vice President Of Clinical Development

  3/3/2014

• Sorrento Therapeutics, Inc. Expands Its Exclusive Rights To Cynviloq™ To Include Australia, Canada And Mexico

  2/10/2014